ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Value-added Medicines (VAM) Development Service Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-9G18992
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Value added Medicines VAM Development Service Market Research Report 2025
BUY CHAPTERS

Global Value-added Medicines (VAM) Development Service Market Research Report 2025

Code: QYRE-Auto-9G18992
Report
January 2025
Pages:77
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Sandoz Inc
Adragos Pharma
Altus Drug Development
Galenicap

Value-added Medicines (VAM) Development Service Market Size

The global market for Value-added Medicines (VAM) Development Service was valued at US$ 553 million in the year 2024 and is projected to reach a revised size of US$ 1059 million by 2031, growing at a CAGR of 10.5% during the forecast period.

Value-added Medicines (VAM) Development Service Market

Value-added Medicines (VAM) Development Service Market

Value-added Medicines Developmen‌t‌ Service usually refers to adding additional value to pharmaceutical products by providing professional technical support, innovative solutions and optimized processes in the drug development and manufacturing process. These services may include the design, synthesis, analysis, optimization, production, quality control and other aspects of drug development to improve drug efficacy, safety, production efficiency and patient experience.
North American market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Value-added Medicines (VAM) Development Service is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Value-added Medicines (VAM) Development Service in Pharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Value-added Medicines (VAM) Development Service include Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Value-added Medicines (VAM) Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Value-added Medicines (VAM) Development Service.
The Value-added Medicines (VAM) Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Value-added Medicines (VAM) Development Service market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Value-added Medicines (VAM) Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Value-added Medicines (VAM) Development Service Market Report

Report Metric Details
Report Name Value-added Medicines (VAM) Development Service Market
Accounted market size in year US$ 553 million
Forecasted market size in 2031 US$ 1059 million
CAGR 10.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Value-added Medicines (VAM) Development Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Value-added Medicines (VAM) Development Service Market growing?

Ans: The Value-added Medicines (VAM) Development Service Market witnessing a CAGR of 10.5% during the forecast period 2025-2031.

What is the Value-added Medicines (VAM) Development Service Market size in 2031?

Ans: The Value-added Medicines (VAM) Development Service Market size in 2031 will be US$ 1059 million.

Who are the main players in the Value-added Medicines (VAM) Development Service Market report?

Ans: The main players in the Value-added Medicines (VAM) Development Service Market are Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma

What are the Application segmentation covered in the Value-added Medicines (VAM) Development Service Market report?

Ans: The Applications covered in the Value-added Medicines (VAM) Development Service Market report are Pharmaceutical Companies, Biotech Companies, Hospitals and Medical Institutions

What are the Type segmentation covered in the Value-added Medicines (VAM) Development Service Market report?

Ans: The Types covered in the Value-added Medicines (VAM) Development Service Market report are Chronic Disease Treatment Drugs, Infectious Disease Treatment Drugs, Tumor Treatment Drugs, Other

Recommended Reports

Drug Development Services

Pharmacovigilance & Safety

Therapeutics & Drugs

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Development Service Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Hospitals and Medical Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Development Service Market Perspective (2020-2031)
2.2 Global Value-added Medicines (VAM) Development Service Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Development Service Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Value-added Medicines (VAM) Development Service Historic Market Size by Region (2020-2025)
2.2.3 Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2026-2031)
2.3 Value-added Medicines (VAM) Development Service Market Dynamics
2.3.1 Value-added Medicines (VAM) Development Service Industry Trends
2.3.2 Value-added Medicines (VAM) Development Service Market Drivers
2.3.3 Value-added Medicines (VAM) Development Service Market Challenges
2.3.4 Value-added Medicines (VAM) Development Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue (2020-2025)
3.1.2 Global Value-added Medicines (VAM) Development Service Revenue Market Share by Players (2020-2025)
3.2 Global Value-added Medicines (VAM) Development Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Development Service Revenue
3.4 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Development Service Revenue in 2024
3.5 Global Key Players of Value-added Medicines (VAM) Development Service Head office and Area Served
3.6 Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
3.7 Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Development Service Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Type (2020-2025)
4.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2026-2031)
5 Value-added Medicines (VAM) Development Service Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Application (2020-2025)
5.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Value-added Medicines (VAM) Development Service Market Size (2020-2031)
6.2 North America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
6.4 North America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Development Service Market Size (2020-2031)
7.2 Europe Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
7.4 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size (2020-2031)
8.2 Asia-Pacific Value-added Medicines (VAM) Development Service Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025)
8.4 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Development Service Market Size (2020-2031)
9.2 Latin America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
9.4 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size (2020-2031)
10.2 Middle East & Africa Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025)
10.4 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altus Drug Development
11.1.1 Altus Drug Development Company Details
11.1.2 Altus Drug Development Business Overview
11.1.3 Altus Drug Development Value-added Medicines (VAM) Development Service Introduction
11.1.4 Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.1.5 Altus Drug Development Recent Development
11.2 TIEFENBACHER GROUP
11.2.1 TIEFENBACHER GROUP Company Details
11.2.2 TIEFENBACHER GROUP Business Overview
11.2.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Introduction
11.2.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.2.5 TIEFENBACHER GROUP Recent Development
11.3 Hyloris Pharmaceuticals SA
11.3.1 Hyloris Pharmaceuticals SA Company Details
11.3.2 Hyloris Pharmaceuticals SA Business Overview
11.3.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Introduction
11.3.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.3.5 Hyloris Pharmaceuticals SA Recent Development
11.4 Adamed
11.4.1 Adamed Company Details
11.4.2 Adamed Business Overview
11.4.3 Adamed Value-added Medicines (VAM) Development Service Introduction
11.4.4 Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.4.5 Adamed Recent Development
11.5 Colonis
11.5.1 Colonis Company Details
11.5.2 Colonis Business Overview
11.5.3 Colonis Value-added Medicines (VAM) Development Service Introduction
11.5.4 Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.5.5 Colonis Recent Development
11.6 Towa International
11.6.1 Towa International Company Details
11.6.2 Towa International Business Overview
11.6.3 Towa International Value-added Medicines (VAM) Development Service Introduction
11.6.4 Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.6.5 Towa International Recent Development
11.7 Galenicap
11.7.1 Galenicap Company Details
11.7.2 Galenicap Business Overview
11.7.3 Galenicap Value-added Medicines (VAM) Development Service Introduction
11.7.4 Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.7.5 Galenicap Recent Development
11.8 Sandoz AG
11.8.1 Sandoz AG Company Details
11.8.2 Sandoz AG Business Overview
11.8.3 Sandoz AG Value-added Medicines (VAM) Development Service Introduction
11.8.4 Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.8.5 Sandoz AG Recent Development
11.9 Adragos Pharma
11.9.1 Adragos Pharma Company Details
11.9.2 Adragos Pharma Business Overview
11.9.3 Adragos Pharma Value-added Medicines (VAM) Development Service Introduction
11.9.4 Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025)
11.9.5 Adragos Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Sandoz Inc
Adragos Pharma
Altus Drug Development
Galenicap
List of Tables
 Table 1. Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Chronic Disease Treatment Drugs
 Table 3. Key Players of Infectious Disease Treatment Drugs
 Table 4. Key Players of Tumor Treatment Drugs
 Table 5. Key Players of Other
 Table 6. Global Value-added Medicines (VAM) Development Service Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Value-added Medicines (VAM) Development Service Market Share by Region (2020-2025)
 Table 10. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Value-added Medicines (VAM) Development Service Market Share by Region (2026-2031)
 Table 12. Value-added Medicines (VAM) Development Service Market Trends
 Table 13. Value-added Medicines (VAM) Development Service Market Drivers
 Table 14. Value-added Medicines (VAM) Development Service Market Challenges
 Table 15. Value-added Medicines (VAM) Development Service Market Restraints
 Table 16. Global Value-added Medicines (VAM) Development Service Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Value-added Medicines (VAM) Development Service Market Share by Players (2020-2025)
 Table 18. Global Top Value-added Medicines (VAM) Development Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) Development Service as of 2024)
 Table 19. Ranking of Global Top Value-added Medicines (VAM) Development Service Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Development Service Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Value-added Medicines (VAM) Development Service, Headquarters and Area Served
 Table 22. Global Key Players of Value-added Medicines (VAM) Development Service, Product and Application
 Table 23. Global Key Players of Value-added Medicines (VAM) Development Service, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Value-added Medicines (VAM) Development Service Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2020-2025)
 Table 27. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2026-2031)
 Table 29. Global Value-added Medicines (VAM) Development Service Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2020-2025)
 Table 31. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2026-2031)
 Table 33. North America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Altus Drug Development Company Details
 Table 49. Altus Drug Development Business Overview
 Table 50. Altus Drug Development Value-added Medicines (VAM) Development Service Product
 Table 51. Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 52. Altus Drug Development Recent Development
 Table 53. TIEFENBACHER GROUP Company Details
 Table 54. TIEFENBACHER GROUP Business Overview
 Table 55. TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Product
 Table 56. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 57. TIEFENBACHER GROUP Recent Development
 Table 58. Hyloris Pharmaceuticals SA Company Details
 Table 59. Hyloris Pharmaceuticals SA Business Overview
 Table 60. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Product
 Table 61. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 62. Hyloris Pharmaceuticals SA Recent Development
 Table 63. Adamed Company Details
 Table 64. Adamed Business Overview
 Table 65. Adamed Value-added Medicines (VAM) Development Service Product
 Table 66. Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 67. Adamed Recent Development
 Table 68. Colonis Company Details
 Table 69. Colonis Business Overview
 Table 70. Colonis Value-added Medicines (VAM) Development Service Product
 Table 71. Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 72. Colonis Recent Development
 Table 73. Towa International Company Details
 Table 74. Towa International Business Overview
 Table 75. Towa International Value-added Medicines (VAM) Development Service Product
 Table 76. Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 77. Towa International Recent Development
 Table 78. Galenicap Company Details
 Table 79. Galenicap Business Overview
 Table 80. Galenicap Value-added Medicines (VAM) Development Service Product
 Table 81. Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 82. Galenicap Recent Development
 Table 83. Sandoz AG Company Details
 Table 84. Sandoz AG Business Overview
 Table 85. Sandoz AG Value-added Medicines (VAM) Development Service Product
 Table 86. Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 87. Sandoz AG Recent Development
 Table 88. Adragos Pharma Company Details
 Table 89. Adragos Pharma Business Overview
 Table 90. Adragos Pharma Value-added Medicines (VAM) Development Service Product
 Table 91. Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2020-2025) & (US$ Million)
 Table 92. Adragos Pharma Recent Development
 Table 93. Research Programs/Design for This Report
 Table 94. Key Data Information from Secondary Sources
 Table 95. Key Data Information from Primary Sources
 Table 96. Authors List of This Report


List of Figures
 Figure 1. Value-added Medicines (VAM) Development Service Picture
 Figure 2. Global Value-added Medicines (VAM) Development Service Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Value-added Medicines (VAM) Development Service Market Share by Type: 2024 VS 2031
 Figure 4. Chronic Disease Treatment Drugs Features
 Figure 5. Infectious Disease Treatment Drugs Features
 Figure 6. Tumor Treatment Drugs Features
 Figure 7. Other Features
 Figure 8. Global Value-added Medicines (VAM) Development Service Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Value-added Medicines (VAM) Development Service Market Share by Application: 2024 VS 2031
 Figure 10. Pharmaceutical Companies Case Studies
 Figure 11. Biotech Companies Case Studies
 Figure 12. Hospitals and Medical Institutions Case Studies
 Figure 13. Value-added Medicines (VAM) Development Service Report Years Considered
 Figure 14. Global Value-added Medicines (VAM) Development Service Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 15. Global Value-added Medicines (VAM) Development Service Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Value-added Medicines (VAM) Development Service Market Share by Region: 2024 VS 2031
 Figure 17. Global Value-added Medicines (VAM) Development Service Market Share by Players in 2024
 Figure 18. Global Top Value-added Medicines (VAM) Development Service Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Value-added Medicines (VAM) Development Service as of 2024)
 Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Development Service Revenue in 2024
 Figure 20. North America Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. North America Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
 Figure 22. United States Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Canada Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
 Figure 26. Germany Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific Value-added Medicines (VAM) Development Service Market Share by Region (2020-2031)
 Figure 34. China Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Japan Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. South Korea Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Southeast Asia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. India Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Australia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
 Figure 42. Mexico Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Brazil Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Share by Country (2020-2031)
 Figure 46. Turkey Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Saudi Arabia Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. UAE Value-added Medicines (VAM) Development Service Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Altus Drug Development Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 50. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 51. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 52. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 53. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 54. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 55. Galenicap Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 56. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 57. Adragos Pharma Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2020-2025)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Nanomedicine Development and Manufacturing Services Market Research Report 2025
Global Commercial Drug Manufacturing Service Market Research Report 2025
Global Dosage Form Development Service Market Research Report 2025
Global Generic Drug Research and Development Services Market Research Report 2024
Global mRNA Vaccine Drugs Development Services Market Research Report 2024
Global Vaccine Development Service Market Research Report 2025
Global Drug Particle Engineering Service Market Research Report 2025
Global Antibody Development Services Market Research Report 2025
Global Antibody Drug CDMO Service Market Research Report 2024
Drug Discovery and Development Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pharmaceutical Analytical Service Market Research Report 2025
Global mRNA Development and Manufacturing Services Market Research Report 2025
Global Pharmaceutical Characterization Service Market Research Report 2025
Global Value Added Services VAS in Retail Market Research Report 2024
Global Value added Medicines VAM Market Research Report 2025
Global Mobile Value Added Services MVAS Market Research Report 2024
Global Small Molecule Drug CDMO Services Market Research Report 2024
Global API Drug Development Service Market Research Report 2024
Global Pharmaceutical Formulation Development Market Research Report 2025
Global GNSS Value added Service Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions